Pendulum T2D Dietary Supplement Impact on GI Symptoms and Glycemic Control in Type 2 Diabetes Patients
This study aims to evaluate the impact of the Pendulum T2D dietary supplement on reducing gastrointestinal symptoms and improving glycemic control in patients with Type 2 Diabetes.
Pendulum Glucose Control formulation for T2D
Treatment Study
Summary
Study start date: January 15, 2021
Actual date on which the first participant was enrolled.Many people with type 2 diabetes experience gastrointestinal (GI) symptoms, which can negatively impact their quality of life. The cause of these symptoms and their relationship with blood sugar control isn't entirely clear. This study aims to explore if modifying the microbiome using the Pendulum T2D dietary supplement can enhance the effectiveness of current treatments and reduce GI symptoms in type 2 diabetes patients. These patients are already on a stable dose of metformin, either alone or with other oral or injectable anti-hyperglycemic agents, and are experiencing GI symptoms. The study is important as it could potentially lead to improved care and quality of life for those with type 2 diabetes who also have GI symptoms. The study is single-site, observational, and will involve 30 patients with type 2 diabetes who have GI complaints and are using one or more oral or injectable anti-hyperglycemic agents. The study will last for 8 weeks, with an option to continue to 6 months for those who wish to keep taking the dietary supplement. Participants will take the Pendulum T2D supplement, and the study will measure changes in GI symptoms using the Gastrointestinal Symptom Rating Scale (GSRS). This scale assesses the impact of various GI symptoms over the past week, with scores ranging from 1 (no discomfort at all) to 7 (very severe discomfort).
Protocol
This section provides details of the study plan, including how the study is designed and what the study is measuring.Treatment Study
Eligibility
Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.Any sex
Biological sex of participants that are eligible to enroll.Over 18 Years
Range of ages for which participants are eligible to join.Healthy volunteers not allowed
If individuals who are healthy and do not have the condition being studied can participate.Criteria
Study Plan
Find out more about all the medication administered in this study, their detailed description and what they involve.One single intervention group is designated in this study
This study does not include a placebo group
Treatment Groups
Group I
ExperimentalStudy Objectives
Primary Objectives
Secondary Objectives
Study Centers
These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.This study has 1 location
USC Westside Center for Diabetes
Los Angeles, United StatesOpen USC Westside Center for Diabetes in Google Maps